The annual public report from the Joint Drug Prevention and Treatment Program’s Independent Program Administrator has been released by Major League Baseball. The stats:
- There were 5,391 total drug tests. 4,022 were urine samples, 1,369 were blood samples;
- There were eight positive tests resulting in discipline. All were for stimulants. Seven of the stimulant tests were for Adderall. One for Methylhexaneamine. I guess that means that there are no more steroids in baseball. Yay!
- There were 13 “non-analytical positives.” That’s baseball code for “Biogenesis dudes.”
- There were 122 therapeutic use exemptions for otherwise banned drugs. 119 of them were for ADD drugs like Adderall. Three were three for hypogonadism. A couple of years ago here was only one for hypogonadism, so that’s on the uptick. On the bright side, two years ago there was a therapeutic use exemption for narcolepsy and now there is none. So the narcoleptic either got better or retired.
The most interesting thing here, to me anyway, continues to be the number of Adderall-users in baseball. It’s estimated that 4.7% of the adult population has ADD. 119 of roughly 1,200 major leaguers on 40-man rosters puts the ADD rate at nearly 10%. Back that number down a little bit for the various guys that shuffle in and out of 400-man rosters and you figure that baseball players have ADD diagnosis at around twice the level of that in the normal population.
Are baseball players more likely to have ADD than the rest of the adult population? Are they just more likely to be diagnosed that way? Or are therapeutic use exemptions for ADD drugs a means of getting something ballplayers have always found beneficial — stimulants — in a legal way?
Former Tigers infielder Casey McGehee has reportedly signed a one-year deal with the Yomiuri Giants of Nippon Professional Baseball, according to FOX Sports’ Ken Rosenthal.
It’s the fourth move the corner infielder has made in the last two seasons after seeing short-term stints with the Marlins, Giants and Tigers. He signed a minor league deal with the Tigers prior to the 2016 season, providing the club with some infield depth behind 24-year-old Nick Castellanos. When Castellanos hit the disabled list in August with a broken hand, McGehee was recalled from Triple-A Toledo for a 30-game stint and slashed .228/.260/.239 with one extra-base hit in 96 PA. His career batting line (.258/.317/.384 over eight seasons) isn’t too shabby, but his age and a long history of knee injuries puts a damper on his potential.
McGehee last appeared in the NPB circuit in 2013, when he signed a one-year, $1.5 million deal with the Tohoku Rakuten Golden Eagles. He spent the bulk of his season at the hot corner, batting an impressive .292/.396/.515 with 28 homers in 590 PA and appearing in the Eagles’ first and only championship run to date.
The deal comes with a club option for 2018, Rosenthal reports, though no figure has been specified.
Free agent left-hander Rich Hill is rumored to be entertaining a three-year, $40+ million offer from the Dodgers, reports Peter Gammons. The Boston Globe’s Nick Cafardo corroborated the report, adding that Hill could receive somewhere between $46 and $48 million from his former team.
Hill, 36, pitched to a 2.12 ERA and 3.91 FIP in back-to-back stints with the Athletics and Dodgers in 2016. While a chronic case of blisters on his pitching hand limited the frequency of his starts, he still figures to be one of the most productive and noteworthy starting pitchers on the market this winter.
The Orioles, Yankees, Red Sox, Rangers and Astros have all been mentioned as potential suitors for the left-hander’s services, though Orioles’ GM Dan Duquette said the club has yet to make a play for Hill and ESPN’s Jim Bowden pointed out that the Red Sox are less involved in trade talks than other interested parties.